Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...

Natural treatments for lupus are typically used as complementary therapies alongside conventional treatments. Learn more ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

In a new study, researchers discovered a potential new gene biomarker, ELF1, a protein coding gene, that can be used to ...

Then there’s physical activity: Many of the symptoms of lupus, such as joint pain, fatigue, and depression, may make patients ...